It was reported yesterday the US Food and Drug Administration (USFDA) has granted approval Novartis' Sandoz unit for Ziextenzo (pegfilgrastim-bmez), a biosimilar to Amgen's Neulasta (pegfilgrastim).
The product has been indicated to decrease the chance of infection caused by low white blood cell count with a fever, a condition called febrile neutropenia. The biosimilar has been approved for use in patients with non-myeloid malignancies who are undergoing treatment with myelosuppressive anti-cancer drugs known for causing febrile neutropenia incidents as side effects.
Sandoz is expected to launch Ziextenzo in the US before the end of the year.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval